The Effects of Modafinil and Methylprednisolone on Neurological Healing in Experimental Spinal Cord Injury
Abstract
Objective: Methylprednisolone remains one of the most extensively studied pharmacological agents in the treatment of acute spinal cord injury; however, concerns regarding its adverse effects have prompted the investigation of alternative therapeutic strategies. This study aimed to evaluate the neurobehavioral and electrophysiological effects of Modafinil administered alone and in combination with Methylprednisolone in an experimental rat model of spinal cord injury.
Methods: Twenty-five male Wistar Albino rats were randomly divided into five groups. Following laminectomy and standardized spinal cord trauma, Modafinil and/or Methylprednisolone were administered according to group allocation. Neurobehavioral recovery was assessed using the Inclined Plane Test, and electrophysiological evaluation was performed using motor evoked potential recordings.
Results: A statistically significant difference in inclined plane angles was observed between the groups on postoperative day 1 (p < 0.01). Groups 4 and 5 demonstrated significantly higher functional scores compared to Group 2, whereas no significant difference was observed between Groups 2 and 3. In within-group analysis, functional improvement between day 1 and day 10 was significant in Groups 4 and 5 but not in Groups 1 and 2. Early post-traumatic amplitudes decreased significantly in all trauma groups. Late amplitude measurements demonstrated significant recovery within treatment groups, with greater improvement observed in the combined treatment group.
Conclusion: Modafinil demonstrated beneficial neurobehavioral and electrophysiological effects in this experimental spinal cord injury model. The combined administration of Modafinil and Methylprednisolone resulted in greater functional and electrophysiological recovery, suggesting a potential synergistic effect. Further experimental and clinical studies are required to clarify its therapeutic role.
Keywords
Modafinil , Methylprednisolone , Spinal Cord Injuries , Motor Evoked Potentials
References
- Lu Y, Shang Z, Zhang W, Pang M, Hu X, Dai Y, et al. Global incidence and characteristics of spinal cord injury since 2000–2021: a systematic review and meta-analysis. BMC Med. 2024;22: 285. doi:10.1186/s12916-024-03514-9
- GBD Spinal Cord Injuries Collaborators. Global, regional, and national burden of spinal cord injury, 1990–2019. Lancet Neurol. 2023;22(11): 1026–1047. doi:10.1016/S1474-4422(23)00287-9
- Fischer GF, Bättig L, Stienen MN, Curt A, Fehlings MG, Hejrati N, et al. Advancements in neuroregenerative and neuroprotective therapies for traumatic spinal cord injury. Front Neurosci. 2024;18: 1372920. doi:10.3389/fnins.2024.1372920
- Montoto‑Marqués A, Benito‑Penalva J, Ferreiro‑Velasco ME, Wright MA, Salvador‑De la Barrera S, Kumru H, et al. Advances and new therapies in traumatic spinal cord injury. J Clin Med. 2025;14(7): 2203. doi:10.3390/jcm14072203
- Fehlings MG, Wilson JR, Tetreault LA, Aarabi B, Anderson P, Arnold PM, et al. A clinical practice guideline for the management of acute spinal cord injury: recommendations on the use of methylprednisolone sodium succinate. Global Spine J. 2017;7(3S): 203S–211S. doi:10.1177/2192568217703085
- Evaniew N, Belley‑Côté EP, Fallah N, Noonan VK, Rivers CS, Dvorak MF. Methylprednisolone for the treatment of patients with acute spinal cord injuries: a systematic review and meta-analysis. Global Spine J. 2017;7(3S): 116S–137S. doi:10.1177/2192568217706366
- Geisler FH, Moghaddamjou A, Wilson JRF, Fehlings MG. Methylprednisolone in acute traumatic spinal cord injury: case‑matched outcomes from NASCIS‑II and Sygen historical data. J Neurosurg Spine. 2023;38(5): 595–606. doi:10.3171/2022.12.SPINE22713
- Liu LJW, Rosner J, Cragg JJ. High‑dose methylprednisolone for acute traumatic spinal cord injury: a meta-analysis. Neurology. 2020;95: 272–274. doi:10.1212/WNL.0000000000009263
- Han J, Chen D, Liu D, Zhu Y. Modafinil attenuates inflammation via inhibiting Akt/NF‑κB pathway in apoE‑deficient mouse model of atherosclerosis. Inflammopharmacology. 2018;26(2): 385–393. doi:10.1007/s10787-017-0387-3
- Wadhwa M, Chauhan G, Roy K, Sahu S, Deep S, Jain V, et al. Caffeine and modafinil ameliorate neuroinflammation and anxious behavior during sleep deprivation by inhibiting microglia activation. Front Cell Neurosci. 2018;12: 49. doi:10.3389/fncel.2018.00049